The ECs advance CTSA Program objectives in high priority areas in clinical and translational science.
CTSA Program Groups Guidance FAQs
|Community Member||A member of the community that includes all stakeholders connected to clinical and translational research. Communities may include but are not limited to non-profit or industry entitiesengaged in translational research, and might include disease advocacy groups, local health providers, community-based organizations, and other national or local communities.|
|CC||CTSA Program Coordinating Center|
|CTSA||Clinical and Translational Science Awards|
|DCI||Division of Clinical Innovation|
|DTF||Domain Task Force|
|IOM||Institute of Medicine|
|NCATS||National Center for Advancing Translational Sciences|
DTFs will propose in their transition plan (due July 31, 2019) to continue as is or propose revised objectives. DTFs also have the option of proposing to sunset.
No; 1 voting member per EC.
ECs may propose any number of WGs. It is the responsibility of the SC to review and approve a maximum of 12 WGs at any time. It is expected that the SC would support and approve WGs in all areas of clinical and translational science with a target of ≤2 WGs from a specific EC.
The ECs will report annually to the SC via an SC teleconference meeting. ECs will report annually to the Consortium via a CTSA Program Webinar. ECs will hold an annual face-to-face meeting.
See CTSA Program Groups Guidance document
WGs are one way that ECs can carry out projects that fill identified gaps and/or further the program objectives.
As SC Co-chairs were appointed by NCATS as the DTF SC Co-Chair member of the lead team they must be nominated (by themselves or others) to be on the Lead Team of the EC and go through the election process. If elected, the EC Lead Team can choose to make them the chair or co-chair of the EC. In this capacity they are not serving as a SC member. For any Working Groups originating from their EC they will have to recuse themselves from WG considerations by the SC due to conflict of interest.
All content will remain available on the CC website on the new EC pages as historical content.
The function of DTFs and ECs is very similar (see Q/A 1 above). The changes are largely to rename the groups to reflect their function and provide the DTFs the opportunity to review and possibly refocus their objectives.
The incoming lead team will decide who will be the chair/co-chair for the coming year.
Each CTSA Program hub is required to have membership on ≥1 EC.
Current DTF members should decide whether to continue participating based upon the final focus of the transitioned EC.
DTFs will propose in their transition plan to continue as is or to revise the objectives, and have the option of proposing to sunset. The focus of some may shift.
WGs consider and develop solutions around a specific clinical and translational science issue. A maximum of 12 active WGs will be supported across the consortium. WGs propose and deliver well-defined projects or deliverables that fill identified translational gaps and/or further the CTSA Program objectives in high priority areas in clinical and translational science.
Yes, but must formally submit a WG proposal for consideration.
No, they can be as long as needed to complete the deliverables up to 24 months
The size of a WG will depend on the project and must be approved by the Steering Committee. As large groups may be unwieldy in terms of meeting timelines and project goals, WGs may propose to allow broad membership but task a smaller core group to do the majority of the work and report back to the larger group for input.
The current DTF will submit a completion plan to the SC for review. The SC may approve a brief extension (e.g., 2 months), request that a proposal for a new WG be submitted, or request that the WG transition to a DF to complete its work.
If an EC wishes to “support/sponsor” the initiation of a specific WG, that WG would fall under that EC.
The number of WG members is not prescribed.
All content will be archived and requests may be made to access the information.
2 years. Requests for additional time require SC review, and may result in transition to a DF.
Anyone in the CTSA Program and a limited number of community members (See CTSA Program Groups Guidance document.)
Most members of the CTSA Program who want to propose and deliver well-defined projects or deliverables that fill identified translational gaps and/or further the CTSA Program objectives in high priority areas in clinical and translational science. For example, WG proposals may be submitted by DF members, hub or pod members, or consortium committees. CLIC, CD2H, and TIN are not allowed to propose WGs through this process, as they have other available resources.
No. An emergent need would be addressed via a SC Task Force.
The DF advance CTSA Program objectives in high priority areas in clinical and translational science by focusing on specific topics and may develop plans for projects that fill identified gaps and/or further the program objectives through a Working Group proposal.
No, but creators and members must register via the CC
No, but DF members are required to register per CTSA Program Groups Guidance document and will be provided a digital workspace by the CC. There is no formal governance for DFs, but they may choose to create one. DFs make decisions on how to operate as a group and whether they have a leadership structure within it.
Unless the CC is notified in advance, DFs will be considered inactive if the workspace is not used for 6 months
Anyone within the CTSA Program
Membership is determined by the initial creator(s), who will serve as the DF POC(s). For example, the creators may wish to have a small group or completely open membership.